METEORIC-HF: Omecamtiv mecarbil fails to improve exercise performance in HFrEF

WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported.
Exercise is a “cardinal manifestation” of HF but is not improved by current medical therapies, G. Michael Felker, MD, MHS, professor of medicine at Duke Clinical Research Institute, said during a late-breaking clinical trial presentation at the American College of Cardiology Scientific Session. In the previous GALACTIC-HF trial, researchers observed that omecamtiv

WASHINGTON — In well-treated patients with chronic HF with reduced ejection fraction, omecamtiv mecarbil did not improve measures of exercise capacity over 20 weeks compared with placebo, researchers reported.
Exercise is a “cardinal manifestation” of HF but is not improved by current medical therapies, G. Michael Felker, MD, MHS, professor of medicine at Duke Clinical Research Institute, said during a late-breaking clinical trial presentation at the American College of Cardiology Scientific Session. In the previous GALACTIC-HF trial, researchers observed that omecamtiv